National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2.2016. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed March 2, 2017.
Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v8-v30. Abstract
Essemann L. Integration of imaging in the management of breast cancer. J Clin Oncol. 2005;23:1601-1602. Abstract
Schaefer FK, Waldmann A, Katalinic A, et al. Influence of additional breast ultrasound on cancer detection in a cohort study for quality assurance in breast diagnosis–analysis of 102,577 diagnostic procedures. Eur Radiol. 2010;20:1085-1092. Abstract
Berg WA. Supplemental screening sonography in dense breasts. Radiol Clin North Am. 2004;42:845-851. Abstract
Warrier S, Tapia G, Goltsman D, et al. An update in breast cancer screening and management. Womens Health. 2016;12:229-239.
Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging. J Clin Oncol. 2008;26:3248-3258. Abstract
Hasson SP, Rubineck T, Ryvo L, et al. Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway. Breast Cancer (Basel). 2013;8:248-255.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687-1717. Abstract
Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet. 2015;386:1341-1352. Abstract
Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010:28:509-518. Abstract
Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139. Erratum in: Lancet. 2002;360:1520.
Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486-492. Abstract
Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet. 2007;369:559-570. Abstract
Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;3:1104-1111.
Van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet. 2011;377:321-331. Abstract
Cumming SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765. Abstract
Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26:2773-2783. Abstract
Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet. 2015;386:433-443. Abstract
Yang GS, Kim HJ, Griffith KA, et al. Interventions for the treatment of aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review and meta-analysis. Cancer Nurs. 2016 June 21. DOI: 10.1097/NCC.0000000000000409. [Epub ahead of print]
Bae K, Yoo HS Lamoury G, et al. Acupuncture for aromatase inhibitor-induced arthralgia: A systematic review. Integr Cancer Ther. 2015;14:496-502. Abstract
Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299-1309. Abstract
Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 2012;30:709-717. Abstract
Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17 Suppl 7:vii10-vii14. Abstract
Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup. J Clin Oncol. 2008;26:1956-1964. Abstract
Goss PE, Pritchard Kl, Robert NJ, et al. Extending aromatase inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209-219. Abstract
Regan MM, Price KN, Giobbie-Hurder A, et al. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Res. 2011;13:209.
Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176. Abstract
Coleman RE. Management of bone metastases. Oncologist. 2000;5:463-470. Abstract
O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015;7:2020-211.
Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016;34:3069-103. Abstract
Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003;(2):CD002747.
Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive Breast Cancer Version 1.2016. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14:32454.
Pritchard KI, Chia SK, Simmons C, et al. Enhancing endocrine therapy combination strategies for the treatment of postmenopausal HR+/HER2-advanced breast cancer. Oncologist. 2017;22:12-24. Abstract
Atkins M, Yasothan U, Kirkpatrick P. Everolimus. Nat Rev Drug Discov. 2009;8:535-536. Abstract
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal HR-positive advanced breast cancer. N Engl J Med. 2012;366:520-529. Abstract
Yardley DA, Noguchi S, Pritchard KL, et al. Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30:870-884. Abstract
Rugo HS, Beck JT, Baselga J, et al. BOLERO-2: health-related quality of life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane [ASCO abstract 125]. J Clin Oncol. 2012;(suppl 27).
Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25:2357-2362. Abstract
Ibrance [package insert]. New York, NY: Pfizer; 2016.
Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancer. Breast Cancer Res. 2016;18:17.
Finn RS, Martin M, Rugo H, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936. Abstract
Finn RS, Crown JP, Etti J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016;18:67.
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-439. Abstract
Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27:1047-1054. Abstract
Bartsch R, Bergen E. ASCO 2016: highlights in breast cancer. Memo. 2016;9:211-214. Abstract
Verma S, Bartlett CH, Schnell P, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist. 2016;21:1165-1175. Abstract
Tian D, Hu Z. CYP3A4-mediated pharmacokinetic interactions in cancer therapy. Curr Drug Metab. 2014;15:808-817. Abstract
Hanley MJ, Cancalon P, Widmer WW, et al. The effect of grapefruit juice on drug disposition. Expert Opin Drug Toxicol. 2011;7:267-286.
Yu Y, Loi CM, Hoffman J, et al. Physiologically based pharmacokinetic modeling of palbociclib. J Clin Pharmacol. 2017;57:173-184. Abstract

CPD

Practical Clinical Insights on New Combination Paradigms in HR-Positive Advanced Breast Cancer

Authors: Sibylle Loibl, MD, PhD
CPD Released: 3/22/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/22/2018, 11:59 PM EST

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists, obstetricians/gynecologists, and pathologists involved in the treatment of patients with hormone receptor (HR)-positive advanced breast cancer.

The goal of this activity is to improve physicians' understanding regarding the use of cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy for treating HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients.

Upon completion of this activity, participants will:

Have greater competence related to the role of CDK 4/6 inhibition for HR-positive, HER2-negative advanced breast cancer patients
Have greater competence related to the recognition and management of AEs associated with the use of CDK 4/6 inhibitors in HR-positive, HER2-negative advanced breast cancer patients

Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator(s)

Sibylle Loibl, MD, PhD

Co-Chair, German Breast Group, Sana Kliniken Offenbach, Breast Cancer Center; Associate Professor, University Frankfurt am Main, Frankfurt, Germany

Disclosures

Disclosure: Sibylle Loibl, MD, PhD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche; Teva Europe

Steering Committee

Nadia Harbeck, MD, PhD

Professor, Breast Center, Department of Obstetrics and Gynecology, University of Munich (LMU), Munich, Germany

Disclosures

Disclosure: Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc

Javier Cortés, MD, PhD

Head, Breast Cancer and Gynecological Tumours, Ramón y Cajal University Hospital, Oncology Department, Madrid, Spain; Clinical Investigator, Breast Cancer Research Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Disclosures

Disclosure: Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bi
Othera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

Angelo Di Leo, MD, PhD

Head, Medical Oncology Unit; Chair, Oncology Department, "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

Disclosures

Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Celgene Corporation; Eisai Co., Ltd; Genomic Health; Ipsen; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; Pierre Fabre; Roche

Stephen R.D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine, Royal Marsden Hospital, London, United Kingdom

Disclosures

Disclosure: Stephen R.D. Johnston, MA, FRCP, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Puma Biotechnology; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Pfizer Inc; Puma Biotechnology
Received grants for clinical research from: GlaxoSmithKline; Pfizer Inc

Xavier Pivot, MD, PhD

Professor, J Minjoz University Hospital, Besancon, France

Disclosures

Disclosure: Xavier Pivot, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speaker's bureau for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Roche

Sunil Verma, MD, MSEd, FRCPC

Professor, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Disclosures

Disclosure: Sunil Verma, MD, MSEd, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

Editors

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Kathryn M. O'Rourke, BA, MA

Medical Writer, WebMD Global, LLC

Disclosures

Disclosure: Kathryn M. O'Rourke, BA, MA, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate CME Clinical Director

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.00 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Practical Clinical Insights on New Combination Paradigms in HR-Positive Advanced Breast Cancer

Authors: Sibylle Loibl, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 3/22/2017

Valid for credit through: 3/22/2018, 11:59 PM EST

processing....

CPD Information

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator(s)

Sibylle Loibl, MD, PhD

Steering Committee

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Angelo Di Leo, MD, PhD

Stephen R.D. Johnston, MA, FRCP, PhD

Xavier Pivot, MD, PhD

Sunil Verma, MD, MSEd, FRCPC

Editors

Deborah Middleton, MS

Kathryn M. O'Rourke, BA, MA

Content Reviewer

Robert Morris, PharmD

CPD

Practical Clinical Insights on New Combination Paradigms in HR-Positive Advanced Breast Cancer

Target Audience and Goal Statement

Disclosures

Moderator(s)

Sibylle Loibl, MD, PhD

Steering Committee

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Angelo Di Leo, MD, PhD

Stephen R.D. Johnston, MA, FRCP, PhD

Xavier Pivot, MD, PhD

Sunil Verma, MD, MSEd, FRCPC

Editors

Deborah Middleton, MS

Kathryn M. O'Rourke, BA, MA

Content Reviewer

Robert Morris, PharmD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Practical Clinical Insights on New Combination Paradigms in HR-Positive Advanced Breast Cancer